Christopher Yea - 01 Nov 2021 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role: Chief Development Officer
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol: KALV
Transactions as of: 01 Nov 2021
Net transactions value: -$90,328
Form type: 4
Filing time: 03 Nov 2021, 16:56:20 UTC
Previous filing: 04 Aug 2021
Next filing: 19 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALV	Common Stock	Sale	$90,328	-5,000	-13%	$18.07	32,969	01 Nov 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69 to $18.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Content

The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69 to $18.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.